| 吴 静,姜 惠,王 丽,束燕雯,孙 璐.沙格列汀与达格列净分别联合阿法骨化醇对T2DM性骨质疏松症患者疗效和25-羟维生素D水平，骨代谢指标的影响[J].,2025,(3):468-473 |
| 沙格列汀与达格列净分别联合阿法骨化醇对T2DM性骨质疏松症患者疗效和25-羟维生素D水平，骨代谢指标的影响 |
| The Efficacy of Saxagliptin and Dapagliflozin Combined with Alfacalcidol in Patients with T2DM Induced Osteoporosis and Their Effects on 25 Hydroxyvitamin D Levels and Bone Metabolism Indicators |
| 投稿时间：2024-11-21 |
| DOI：10.13241/j.cnki.pmb.2025.03.009 |
| 中文关键词: 沙格列汀 达格列净 阿法骨化醇 T2DM 骨质疏松症 疗效 25（OH）D 骨代谢指标 |
| 英文关键词: Saxagliptin Dapagliflozin Alfacalcitriol T2DM Osteoporosis Therapeutic effect 25（OH）D Bone metabolism indicators |
| 基金项目:江苏省老年健康科研项目（LKM2022081）；镇江市科技计划项目（SH2022045）；
镇江市重点研发计划（社会发展）项目（FZ2022092） |
|
| 摘要点击次数: 0 |
| 全文下载次数: 1 |
| 中文摘要: |
| 摘要 目的：对比研究沙格列汀与达格列净分别联合阿法骨化醇对T2DM性骨质疏松症（DOP）患者疗效、25-羟维生素D[25（OH）D]及骨代谢指标的影响。方法：选入2021.4~2024.4收治的DOP患者84例，分为沙格列汀组（42例）和达格列净组（42例），两组均联合阿法骨化醇治疗。比较临床疗效、25（OH）D水平及骨代谢指标。结果：（1）两组治疗后FPG、2hPG、HbA1c降低（P＜0.05），组间比较无差异（P＞0.05）。（2）两组治疗后BMD、血清25（OH）D和OC升高，PINP降低（P＜0.05），而沙格列汀组升高/降低幅度明显大于达格列净组（P＜0.05）；（3）沙格列汀组治疗总有效率显著高于达格列净组（95.24% vs. 76.19%，P＜0.05）。（4）两组均未见明显不良反应。结论：沙格列汀与达格列净均可有效控制血糖水平，而前者在增加BMD、改善骨代谢指标、提高DOP整体疗法方面更具优势。 |
| 英文摘要: |
| ABSTRACT Objective: To compare the therapeutic effects of saxagliptin and dapagliflozin combined with alfacalcidol on patients with type 2 diabetes induced osteoporosis (DOP), as well as their effects on 25 hydroxyvitamin D [25 (OH) D] and bone metabolism indicators. Methods: 84 DOP patients admitted from 2021.4 to 2024.4 were divided into saxagliptin (42) and dagliflozin (42). Both groups were combined with alfacaxiol. Clinical efficacy, 25 (OH) D level, and bone metabolism parameters were compared. Results: (1) FPG, 2 hPG, and HbA 1 c decreased after the two treatment groups (P<0.05), and there was no difference between the groups (P>0.05). (2) BMD, serum 25 (OH) D and OC increased, and PINP decreased (P<0.05), while the increase / decrease in saxagliptin group was greater than that in dagagliflozin group (P<0.05); (3) The total effective rate of the saxagliptin group was significantly higher than that of the dapagliflozin group (95.24% vs. 76.19%, P<0.05). (4) No significant adverse reactions were observed in both groups. Conclusion: Both saxagliptin and dapagliflozin can effectively control blood glucose levels, with the former having more advantages in increasing BMD, improving bone metabolism indicators, and enhancing overall DOP therapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
